CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.
about
Nanoparticle-based targeted therapeutics in head-and-neck cancerProtein kinase CK2 and human malignant tumorsTenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in miceCasein kinase II controls TBK1/IRF3 activation in IFN response against viral infection.IL-6 stabilizes Twist and enhances tumor cell motility in head and neck cancer cells through activation of casein kinase 2.Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.Emergence of protein kinase CK2 as a key target in cancer therapyCK2 phosphorylates and inhibits TAp73 tumor suppressor function to promote expression of cancer stem cell genes and phenotype in head and neck cancer.Restoration of miR-1228* expression suppresses epithelial-mesenchymal transition in gastric cancerUnraveling regulatory programs for NF-kappaB, p53 and microRNAs in head and neck squamous cell carcinoma.miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9.Protein kinase CK2α is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genesPreclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapyMEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.Hierarchical phosphorylation within the ankyrin repeat domain defines a phosphoregulatory loop that regulates Notch transcriptional activityTenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cellsNovel Anthra[1,2-c][1,2,5]Thiadiazole-6,11-Diones as Promising Anticancer Lead Compounds: Biological Evaluation, Characterization & Molecular Targets DeterminationΔNp63 versatilely regulates a Broad NF-κB gene program and promotes squamous epithelial proliferation, migration, and inflammationCK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target.Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.Protein kinase CK2α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma.Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenograftsSystemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors.CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer.Developments in the use of nanocapsules in oncology.Casein kinase: the triple meaning of a misnomer.Casein kinases as potential therapeutic targets.Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer.Dissociation of MIF-rpS3 complex and sequential NF-κB activation is involved in IR-induced metastatic conversion of NSCLC.Targeted nanoparticle for head and neck cancers: overview and perspectives.Casein kinase 2 regulates the mRNA-destabilizing activity of tristetraprolin.Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models.Characterizing the convergence of protein kinase CK2 and caspase-3 reveals isoform-specific phosphorylation of caspase-3 by CK2α': implications for pathological roles of CK2 in promoting cancer cell survival.Cancer-type dependent expression of CK2 transcripts.Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis.
P2860
Q26999699-043E9710-C1BE-4BCA-9D2D-38467E862869Q27026335-94DC8778-B5F3-4B31-AEA6-653D4449757EQ28543800-1D140179-D892-4518-8932-5F46EF17C531Q30373058-D375AEA0-09A0-4FC6-9391-E58623F30354Q33894901-6F1D7A30-5E9E-4A4A-BFAD-41FFBD03F4AAQ34020978-63B4147E-B416-4A5C-BE84-AE62B00FB9F4Q34046848-36853BE8-76F2-49D3-B572-90A234EBB525Q34417563-C6FE7910-FBAB-4A7A-8688-4A68D3123961Q34648156-D8D9C60F-A133-4ED5-8F1E-BD27E9D50A71Q34998769-6D3F4B22-C446-4B63-8FFA-954D54C6201CQ35009302-64E83F53-0DC6-47A0-91F7-3482BE09D56FQ35094836-55D19CEA-42D4-468C-BFE1-B018ED9D6289Q35132090-0A9EDFE9-B95F-4B06-877D-E81B5706823DQ35197507-821BD1B2-8DC2-4E60-8D7C-EA960B6D1944Q35309521-FBA81ED7-49B6-4E82-8AA6-784647A55FCEQ35423247-B3448DAB-3060-40CF-AA88-261E84EF27D5Q35577635-9147EB48-41F4-4546-B3D8-6FAC5597AAFAQ35996034-979F288C-D93A-4A90-BC51-3AF2DC7E151DQ36238438-4C9AC435-EFCD-42EB-A8B7-96C840E00B36Q36263671-58F2D787-2685-4146-ABE3-72B16DEA46BAQ36326939-2915BFD1-4BED-4ADA-A0E0-25834AD80FB3Q36544222-D140AA05-A522-4D8A-AFD2-675764CC7D86Q37073686-FCAFED85-2824-41E6-B1DB-4BCC8197646CQ37487082-321A7EF2-E1EE-49BE-BF26-BAC4A0DA09D5Q37641686-1585C767-B737-4E48-A785-D027318E4EACQ37731329-BCD36021-A1DA-4200-8277-BDC62A9E9574Q38117157-F9677021-D132-4541-A54C-FF393368E869Q38211598-2EE6C02B-1E57-47C0-86E0-2EDD95500026Q38632634-E33BFFE3-5173-4E5D-A04E-E9322878D338Q38740809-4F05A7E4-5D8A-405A-A98F-A5134F746DCEQ38883785-1FFF6491-0B64-4372-A1E5-758D6296E16FQ39226270-88024FEC-8892-4C4A-BB7D-06117B733C1EQ39555596-EB05D6AB-AEE1-4CE8-9164-C5CB8E717D3DQ41582923-34AE4456-110A-46DC-90E7-8EE31EF6F735Q43078357-CB3088B8-20EC-4014-8244-97A58567AFDEQ47114281-7E3C88CE-2E69-478C-BF43-5DD7E72E13BAQ54384094-2BCF0308-415E-4DDE-9346-FE7343BED27C
P2860
CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
CK2 modulation of NF-kappaB, T ...... vo via sub-50-nm nanocapsules.
@ast
CK2 modulation of NF-kappaB, T ...... vo via sub-50-nm nanocapsules.
@en
type
label
CK2 modulation of NF-kappaB, T ...... vo via sub-50-nm nanocapsules.
@ast
CK2 modulation of NF-kappaB, T ...... vo via sub-50-nm nanocapsules.
@en
prefLabel
CK2 modulation of NF-kappaB, T ...... vo via sub-50-nm nanocapsules.
@ast
CK2 modulation of NF-kappaB, T ...... vo via sub-50-nm nanocapsules.
@en
P2093
P2860
P1476
CK2 modulation of NF-kappaB, T ...... ivo via sub-50-nm nanocapsules
@en
P2093
Carter Van Waes
Gretchen Unger
Khalil Ahmed
Michael Hu
Oumou T Diallo
Pattatheyil Arun
Reza Ehsanian
Vicci Korman
Xinping Yang
P2860
P304
P356
10.1158/1078-0432.CCR-09-3200
P407
P577
2010-04-06T00:00:00Z